Literature DB >> 9889433

The treatment of hypertrophic scars and keloids.

B Berman1, F Flores.   

Abstract

Keloid and hypertrophic scarring develop as a result of a proliferation of dermal tissue following skin injury. It is generally thought that tension plays a major pathophysiologic role. These proliferative scars are characterized by increased collagen and glycosaminoglycan content, as well as increase collagen turnover. The therapeutic management of hypertrophic scars and keloids includes occlusive dressings, compression therapy, intralesional corticosteroid injections, cryosurgery, excision, radiation therapy, laser therapy, interferon therapy and other promising, lesser known therapies directed at collagen synthesis. Although the most commonly used occlusive dressings include silicone based materials, the anti-keloidal effect is the result of the occlusion and hydration effected rather than the silicone itself. Pressure devices, through local tissue hypoxia, have proven effective in reducing scar height. Intralesional steroids decrease the connective tissue components and scar volume. Post-operative steroid injections reduce keloid recurrence to less than 50%. Cryosurgery is most effective when combined with intralesional corticosteroids. Excision only of hypertrophic scars and keloids results in 45-100% recurrence. Radiation therapy, using various protocols, has been a safe and efficacious modality in reducing recurrence. The CO2, Nd:YAG, and Argon lasers have been used as destructive modalities for the treatment of proliferative scarring. The pulsed-dye laser offers symptomatic improvement and reduces the erythema associated with these scars. Intralesional interferon -gamma and -alpha 2b have been used successfully to decrease scar height and reduce the number of post-operative recurrences.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9889433

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  20 in total

1.  Keloids: pathogenesis, clinical features, and management.

Authors:  Chuma J Chike-Obi; Patrick D Cole; Anthony E Brissett
Journal:  Semin Plast Surg       Date:  2009-08       Impact factor: 2.314

2.  A spontaneous skin lesion.

Authors:  Josie McCabe; Zoe Blades; Emmet E McGrath
Journal:  CMAJ       Date:  2008-12-02       Impact factor: 8.262

3.  Role of CD14 and TLR4 in type I, type III collagen expression, synthesis and secretion in LPS-induced normal human skin fibroblasts.

Authors:  Hongming Yang; Juncong Li; Yihe Wang; Quan Hu
Journal:  Int J Clin Exp Med       Date:  2015-02-15

4.  Association of CD14 and TLR4 with LPS-stimulated human normal skin fibroblasts in immunophenotype changes and secretion of TGF-β1 and IFN-γ.

Authors:  Hongming Yang; Juncong Li; Yihe Wang; Quan Hu
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

5.  [Hyperplastic scars and keloids. Part I: basics and prevention].

Authors:  A Baisch; F Riedel
Journal:  HNO       Date:  2006-11       Impact factor: 1.284

6.  Recombinant human endostatin reduces hypertrophic scar formation in rabbit ear model through down-regulation of VEGF and TIMP-1.

Authors:  Peng Wang; Li-Zhu Jiang; Bin Xue
Journal:  Afr Health Sci       Date:  2016-06       Impact factor: 0.927

Review 7.  The evidence for the role of transforming growth factor-beta in the formation of abnormal scarring.

Authors:  Richard L Chalmers
Journal:  Int Wound J       Date:  2011-03-30       Impact factor: 3.315

8.  Topical Silicone Sheet Application in the Treatment of Hypertrophic Scars and Keloids.

Authors:  Iris Westra; Hth Pham; Frank B Niessen
Journal:  J Clin Aesthet Dermatol       Date:  2016-10-01

9.  A comparative clinical study on role of 5-flurouracil versus triamcinolone in the treatment of keloids.

Authors:  Anil K Saha; Madhumita Mukhopadhyay
Journal:  Indian J Surg       Date:  2012-01-10       Impact factor: 0.656

10.  Cell permeant peptide analogues of the small heat shock protein, HSP20, reduce TGF-beta1-induced CTGF expression in keloid fibroblasts.

Authors:  Luciana B Lopes; Elizabeth J Furnish; Padmini Komalavilas; Charles R Flynn; Patricia Ashby; Adam Hansen; Daphne P Ly; George P Yang; Michael T Longaker; Alyssa Panitch; Colleen M Brophy
Journal:  J Invest Dermatol       Date:  2008-09-11       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.